ChemoMetec stock

CHEMM · Nasdaq Copenhagen · DKK

Compare ChemoMetec
kr 682.00Change from previous close: −2.92%Absolute change: −kr 20.50

Close · November 20, 2026

Price history

−10.26% over the period

1 year: from kr 760.00 (November 20, 2025) to kr 682.00 (November 20, 2026), −10.26%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026kr 682.00
October 30, 2026kr 611.00
September 30, 2026kr 523.00
August 31, 2026kr 496.60
July 31, 2026kr 432.60
June 30, 2026kr 362.20
May 29, 2026kr 375.00
April 30, 2026kr 320.00
March 31, 2026kr 300.80
February 27, 2026kr 420.40
January 30, 2026kr 609.50
December 30, 2025kr 687.50
November 28, 2025kr 782.50
November 20, 2025kr 760.00

At a glance

  • The company

    Develop and sell analytical equipment for cell counting and analysis used in cell therapy, pharmaceutical development, and quality control

  • Latest results

    Quarter to September 30, 2026 · EPS kr 5.76 (estimate kr 3.92)

TickerLandia's take on ChemoMetec

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 235.20
52-wk highkr 788.00

−13.45% from the 52-week high

Analysts · 3 analysts

Average targetkr 780.00+14.37% vs. price

Buy 3 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: ChemoMetec

Compared with similar companies: very high profitability, very high financial strength, and very high price.

Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

ChemoMetec is priced as in the past and pricier than similar companies

On the latest fiscal year's earnings (2026), ChemoMetec's P/E today is 58.8, in line with the median of its last 10 fiscal years (58.5; between 31.2 and 166.1 from 2017 to 2026). ChemoMetec's P/E (trailing 12 months): 59.9, +107% against the median of a group of 10 similar companies (28.9).

P/E compared with its history

Compared with 10 similar companies

ChemoMetec's metrics compared with similar companies
MetricChemoMetecPosition in the groupBand
P/E (trailing 12 months)59.9High
Forward P/E38.8High
Operating margin49.1%High
ROE28.6%High
Debt/equity0.01Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: ChemoMetec. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

kr 262.04M

Latest quarter · Q2 2026

Net income

kr 107.86M

Latest quarter · Q2 2026

Quarterly net margin

41.2%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
kr 11.92B
P/E
59.9
EPS
kr 11.60
Volume
37.75K
Daily trading
€5.48M

How ChemoMetec is changing

All results
  • Revenue grew 12.7% a year on average over the last 5 years

  • Operating margin fell from 51.9% to 49.1%

  • Profits turn into cash: free cash flow equal to 91% of net income

Returns

ChemoMetec returns with dividends

kr 1,000 invested in ChemoMetec 5 years ago, on November 22, 2021, would be worth kr 736 today with dividends reinvested: −26.36% in total, −5.94% per year. On price alone it would be kr 707 (−29.29%).

PeriodChemoMeteckr 1,000 becomes
1 month+18.40%kr 1,184
6 months+99.42%kr 1,994
Year to date−0.80%kr 992
1 year−10.26%kr 897
3 years+90.37%kr 1,904
5 years−26.36%kr 736
10 years+1,865.42%kr 19,654

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

ChemoMetec: technical analysis

ChemoMetec shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 39.5% below its all-time closing high (kr 1,128.00, September 23, 2021).

Trend
No clear trend
RSI (14 sessions)
59
Between 30 and 70
vs 200-session average
+53.54%

Support and resistance

Price areas where ChemoMetec has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistancekr 736.25+7.95%4 touches, last on November 10, 2026
  2. Last pricekr 682.00
  3. Supportkr 601.75−11.77%2 touches, last on November 3, 2026
  4. Supportkr 534.25−21.66%2 touches, last on September 21, 2026
  5. Supportkr 464.80−31.85%2 touches, last on September 11, 2026

Volatility and risk

Volatility (60 sessions, annualised)
42.4%
Largest fall in the last year
−69.74%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

ChemoMetec: seasonality

Average monthly price change over 20 years

+7.8%Jan+3.1%Feb−4.2%Mar+1.8%Apr+4.1%May+0.9%Jun+7.7%Jul+2.9%Aug−2.8%Sep+5.9%Oct+4.1%Nov+1.1%Dec

Over the last 20 years, the strongest month for ChemoMetec has been January: +7.80% on average, positive in 11 years out of 20. The weakest has been March: −4.24% on average, positive in 6 years out of 20. November, the current month, has been positive in 9 years out of 19 (+4.08% on average).

Show chart data
MonthAverageMedianPositive years
January+7.80%+4.18%11 of 20
February+3.10%+1.92%12 of 20
March−4.24%−2.77%6 of 20
April+1.77%−0.31%9 of 20
May+4.09%+5.52%13 of 20
June+0.91%−3.33%9 of 20
July+7.68%+2.70%13 of 20
August+2.85%+2.81%12 of 20
September−2.78%+1.26%11 of 20
October+5.95%+0.67%10 of 20
November+4.08%0.00%9 of 19
December+1.15%−3.45%6 of 19

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

ChemoMetec and its competitors

Analytical equipment for cell counting and analysis forms the core of the business of ChemoMetec, which sells its instruments in the United States, Canada, Europe and other international markets. Its NucleoCounter range, including the NC-3000 image cytometer, the NC-250 automated cell analyzer and the NC-203 cell counter for complex samples, serves customers working on advanced therapies, oncology and stem cell studies, and the development and production of medicines. The line also includes the SP-100 automated sperm cell counter for animal reproduction and the XcytoMatic 40 cell density and viability analyzer.

Headquarters
Allerød, Denmark
Employees
174
Founded
1997
Chief executive
Martin Behrens
ChemoMetec and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
ChemoMetecCHEMM$1.75B49.1%59.9+99.42%
El.En.ELN$1.44B14.7%20.7+10.78%
ElektaEKTA.B$2.27B9.2%—+1.17%
Medacta GroupMOVE$2.41B15.2%27.7−30.49%
GN Store NordGN$2.46B10.9%90.2+22.10%
AmbuAMBU.B$3.4B13.2%36.7+32.33%

Same industry or related industries, similar size. Compare ChemoMetec with its competitors · Full profile